Current and Emerging CAR T-Cell Therapies in Cancer Care

Join us for this expert-led, live-streamed symposium to get up to date on the latest clinical data informing optimal use of CAR T-cells in cancer treatment, including practical considerations for approved agents, emerging clinical data with investigational strategies, and adverse event.

Not an official event of the 2021 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or Conquer Cancer.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Agenda

  • Welcome
  • CAR T-cell therapy in B-cell NHL, CLL, ALL, and multiple myeloma
    • Overview of clinical trial data, current indications, and practical considerations for axicabtagene ciloleucel, brexucabtagene autoleucel, idecabtagene vicleucel, lisocabtagene maraleucel, and tisagenlecleucel
    • Practical insights for incorporating CAR T-cells into treatment
    • Patient identification and determining what disease-related or patient-related factors correlate with best long-term response
    • Emerging clinical data with investigational CAR T-cell therapy strategies
  • Managing CAR T-cell–mediated toxicities
  • Audience question and answer session

Events

Date / Time
Event Details

Faculty

Faculty
Caron A. Jacobson, MD

Medical Director, Immune Effector Cell Therapy Program
Assistant Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Faculty
Jae H. Park, MD

Associate Member
Leukemia Service and Cellular Therapeutics Center
Memorial Sloan Kettering Cancer Center
New York, New York

Faculty
Noopur Raje, MD

Goal Statement
The goal of this activity is to improve the knowledge, competence, and performance of physicians and other healthcare providers so they can confidently and competently integrate CAR T-cell therapy into their clinical practices.

Target Audience
This program is intended for physicians and other healthcare providers who treat and manage patients with leukemia, lymphoma, or myeloma who are candidates for CAR T-cell therapies.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Identify patients who are eligible and most likely to benefit from CAR T-cell therapy
  • Integrate into practice clinical trial data on CAR T-cell–based therapies for the treatment of patients with leukemia and lymphoma
  • Evaluate emerging clinical data and novel approaches to CAR T-cell therapy for patients with myeloma
  • Based on the current best evidence, implement strategies for managing toxicities associated with CAR T-cell therapy
  • Appraise ongoing clinical trials evaluating CAR T-cell therapy for the treatment of patients with hematologic malignancies and solid tumors

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.